Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma-Reference-Cited by-同舟云学术

Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma

Published:2017-11 Issue:9 Volume:32 Page:309-319
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Roberson Peter L.¹,Smith Lauren B.²,Morgan Meredith A.¹,Schipper Matthew J.¹,Wilderman Scott J.³,Avram Anca M.³,Kaminski Mark S.⁴,Dewaraja Yuni K.³

Affiliation:

1. Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.

2. Department of Pathology, University of Michigan, Ann Arbor, Michigan.

3. Department of Radiology, University of Michigan, Ann Arbor, Michigan.

4. Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.2017.2182

Reference27 articles.

1. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience

2. 131I-Tositumomab Radioimmunotherapy: Initial Tumor Dose–Response Results Using 3-Dimensional Dosimetry Including Radiobiologic Modeling

3. Quantification of Dose Nonuniformities by Voxel-Based Dosimetry in Patients Receiving90Y-Ibritumomab-Tiuxetan

4. Tumor-Absorbed Dose Predicts Progression-Free Survival Following 131I-Tositumomab Radioimmunotherapy

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dosimetry with single photon emission tomography (SPECT);Nuclear Medicine and Molecular Imaging;2022

2. Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice;Journal of Nuclear Medicine;2021-12